#
Drug Candidates
Indication(s)
Pre-clinical
IND
Phase 1
Phase 2
Phase 3 / Pivotal
NDA
Oncology
Code
Phase
Socazolimab
1L Cervical Cancer, 1L ES-SCLC
Registration Filing
ZK050
Cancer Breakthrough Pain (Staccato®)
Registration Filing
ZK092
Solid tumor
Registration Filing
ZK2401
Solid tumor
Registration Filing
ZK2501
Solid tumor
Registration Filing
ZK2502
Solid tumor
Registration Filing
ZK2503
Solid tumor
Registration Filing
ZK2504
Solid tumor
Registration Filing
ZK2505
Solid tumor
Registration Filing
ZK2601
Solid tumor
Registration Filing
ZK057
Multiple Myeloma
Registration Filing
ZK041
Malignant glioma during surgery: visualization of malignant tissue
Registration Filing
Rare Disease
Code
Phase
ZK040
Pulmonary hypertension
Registration Filing
ZK063
Osteogenesis imperfecta
Registration Filing
ZK052
Thrombotic Thrombocytopenic Purpura
Registration Filing
ZK037
Respiratory distress syndrome (RDS) in premature newborns
Registration Filing
ZK094
Pulmonary hypertension
Registration Filing
Central Nervous System (2)
Code
Phase
ZK039
Depression
Registration Filing
Staccato® alprazolam (1)
Acute treatment of epileptic seizures
Registration Filing
Staccato® apomorphine
Parkinson’s disease OFF Episodes
Registration Filing
Staccato® granisetron
Cyclic Vomiting Syndrome (CVS)
Registration Filing
Staccato® pramipexole
Acute Restless Legs Syndrome
Registration Filing
ZK093
Depression
Registration Filing
Note 1: Staccato alprazolam (“STAP”) is out-licensed to UCB for development and commercialization worldwide; Nova Pneuma Inc., a wholly-owned subsidiary of Lee’s Pharma, owns the right as licensor and manufacturer of STAP
Note 2: Staccato® products franchise are under global trials
Note 2: Staccato® products franchise are under global trials
